Breast Cancer Research

Top Research Topics at Breast Cancer Research?

The journal primarily tackles Breast cancer, Surgical oncology, Internal medicine, Oncology and Cancer research. Breast cancer studies tackled cover an aspect of the field of Cancer. The work on Surgical oncology tackled in it brings together disciplines like Alternative medicine, Radiology, Disease and Gene expression profiling.

The Internal medicine study featured in the journal draws parallels with the field of Endocrinology. Issues in Oncology were discussed, taking into consideration concepts from other disciplines like Odds ratio, Case-control study, CA15-3, Hazard ratio and Cohort. The Cancer research works featured in it incorporate elements from Cell growth, Cancer cell, Carcinogenesis, Signal transduction and Metastasis.

The majority of Estrogen receptor studies presented zero in on Estrogen receptor alpha.

• Breast cancer (79.08%)
• Surgical oncology (44.96%)
• Internal medicine (38.09%)

What are the most cited papers published in the journal?

• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer (1540 citations)
• Choosing the right cell line for breast cancer research (953 citations)
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (916 citations)

Research areas of the most cited articles at Breast Cancer Research:

The published articles tackle a plethora of topics, such as Breast cancer, Internal medicine, Cancer research, Surgical oncology and Oncology. The Breast cancer studies which were featured in the journal publications aim to expound on the research in Cancer. The published papers explore issues in Cancer research which can be linked to other research areas like Cell growth, Cancer cell, Carcinogenesis, Signal transduction and Metastasis.

What topics the last edition of the journal is best known for?

• Cancer
• Gene
• Internal medicine

The previous edition focused in particular on these issues:

The journal covers a variety of subjects, including Breast cancer, Cancer research, Surgical oncology, Internal medicine and Oncology. The featured Breast cancer research is covered under the field of Cancer. The journal goes beyond the discussion of Cancer research as it connects it with closely related disciplines like

• Metastasis together with Tumor progression,
• Carcinogenesis and Epithelial–mesenchymal transition most often made with reference to Cancer cell..

The tackled Surgical oncology research is interrelated with Estrogen receptor which concerns subjects like Estrogen and Epidemiology. The journal explores research in Internal medicine and the adjacent study of Gastroenterology. While Oncology is the key highlight in it, it also covered some subjects on Triple-negative breast cancer and PD-L1 and Immunohistochemistry.

The most cited articles from the last journal are:

• Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. (9 citations)
• Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. (7 citations)
• Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy (7 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Breast Cancer Research (based on the number of publications) are:

• Per Hall (53 papers) published 1 paper at the last edition, 1 less than at the previous edition,
• Valerie Speirs (51 papers) absent at the last edition,
• Kamila Czene (49 papers) published 1 paper at the last edition the same number as at the previous edition,
• Douglas F. Easton (47 papers) published 2 papers at the last edition, 1 less than at the previous edition,
• John L. Hopper (45 papers) published 1 paper at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Breast Cancer Research (based on the number of publications) are:

• University of Cambridge (175 papers) published 8 papers at the last edition, 1 more than at the previous edition,
• Harvard University (175 papers) published 7 papers at the last edition, 1 more than at the previous edition,
• University of Texas MD Anderson Cancer Center (146 papers) published 2 papers at the last edition, 3 less than at the previous edition,
• Karolinska Institutet (117 papers) published 4 papers at the last edition, 3 less than at the previous edition,
• National Institutes of Health (115 papers) published 5 papers at the last edition, 2 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 6.12% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 30.43% were posted by at least one author from the top 10 institutions publishing in the journal. Another 13.04% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 18.48% of all publications and 38.04% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Medical Research

For budding health professionals interested in research and Oncology, the field of breast cancer research offers numerous opportunities to contribute to expanding the frontiers of knowledge and potentially informing more effective treatments. For nurses in particular, involvement in research not only provides career advancement opportunities, but it also promotes evidence-based practice which enhances patient care.

If you are a nurse based in Mississippi and want to venture into breast cancer research, or any area of medical research, the first step is to ensure you possess the appropriate qualifications and licensure necessary for the role. Depending on the type of research role you will veer into, an advanced practice nursing degree may be required. Coupled with the right state licensure, this can open doors to numerous opportunities in medical research. Explore more about the pathway to obtaining your licensure, and the associated costs by visiting mississippi nursing license requirements nursing license cost.

Breast cancer research, like other areas of medical research, requires a dedicated team of professionals, including physicians, oncologists, radiologists, pathologists, biostatisticians, and nurses. Each plays a crucial role in driving meaningful scientific exploration and discovery. Your contribution as a nurse in this field is invaluable and could mark the difference in our continued fight against diseases like breast cancer.